Wockhardt Limited announced the launch of the Wockhardt Antibiotic Academy, a national initiative dedicated to fostering patient-centric scientific dialogue and advancing continuous medical education to combat antimicrobial resistance (AMR).
With approximately 10 lakh patients in India dying annually due to multidrug-resistant infections over four times the annual loss of life experienced during the COVID-19 pandemic,the Academy addresses an urgent public health crisis. Designed as an open-access scientific learning platform for registered healthcare professionals across India, the initiative aims to facilitate knowledge exchange, real-world clinical evidence sharing, and evidence-based decision-making at the patient’s bedside.
“There is an urgent need not only to have a new antibiotic like Zaynich, but also to have a science-based platform that fosters constructive dialogue on antimicrobial resistance and its appropriate management,” said Dr. Habil Khorakiwala, Founder Chairman of Wockhardt. “It is essential to use the right antibiotic for the right patient at the right time. We hope this Academy will create a deeper understanding of the current realities of drug resistance and promote evidence-based solutions that enable clinicians to save patients’ lives.”
Dr. Subramaniam Swaminathan, President of the Clinical Infectious Diseases Society, India, highlighted the initiative’s clinical impact: “Resistance is not solved by guidelines alone. It is solved at the patient’s bedside, one clinical decision at a time. Antimicrobial stewardship continues to evolve… Any initiative that brings clinicians together to exchange knowledge and remain closely connected to science is a step in the right direction.”
Through the Academy, Wockhardt will facilitate interactions with national and international infectious disease experts, uniting clinicians, scientific societies, and hospitals nationwide.
Written by: Pragna Biswas
